- Report
- December 2024
- 150 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- May 2024
- 139 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- October 2024
- 184 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- July 2024
- 202 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- December 2024
- 84 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Clinical Trials
- November 2024
- 80 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Clinical Trials
- August 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- April 2025
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- January 2025
- 200 Pages
Global
From €4546EUR$4,995USD£3,897GBP
- Report
- November 2018
- 147 Pages
Global
From €1251EUR$1,375USD£1,073GBP
€2503EUR$2,750USD£2,146GBP
- Report
- November 2023
- 140 Pages
Global
From €4050EUR$4,450USD£3,472GBP
- Report
- February 2024
- 168 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- July 2023
- 135 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- July 2023
- 67 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- December 2023
- 168 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- October 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,458GBP
- Report
- October 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,458GBP
- Report
- November 2023
- 189 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2024
- 112 Pages
Global
From €4323EUR$4,750USD£3,706GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more